Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Phase 2

Completed

• Conditions: Von Hippel-Lindau Disease; Retinal Hemangioblastoma; CNS Hemangioblastoma
• Interventions: Drug: PTK787/ZK 222584

• Registration Number: NCT00052013
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of angiogenesis (new blood vessel growth).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-01-21
• Study First Submitted QC: 2003-01-21
• Study First Posted: 2003-01-22
• Study Start: 2003-02
• Primary Completion: 2006-06
• Status Verified: 2011-02
• Last Update Submitted: 2017-03-02
• Last Update Posted: 2017-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
PTK787/ZK 222584	PTK787/ZK 222584	-

Primary Outcome Measures

Name	Time	Method
Evaluate efficacy

Secondary Outcome Measures

Name	Time	Method
To explore the correlation of the pharmacokinetics
Evaluate changes in dynamic contrast enhanced magnetic resonance imaging
To assess changes in surrogate markers of angiogenesis

Trial Locations

Locations (2)

Dana Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States